TB-500 Research Guide: Potential Benefits, Evidence and COAs

What is TB-500?

TB-500 is a name associated with a synthetic fragment of thymosin beta-4 (Tβ4), a peptide involved in actin biology and cell movement. Full-length Tβ4 contains 43 amino acids; the shorter fragment discussed in analytical research contains the LKKTETQ sequence. A 2012 analytical study identified an acetylated version of this fragment in a preparation labelled TB-500. The name on a vial alone should not replace confirmation of its sequence and identity. TB-500 analytical study

TB-500 and thymosin beta-4: why the distinction matters

A fragment and its full-length parent peptide are different research materials. Sequence, formulation and experimental route can all affect results. A paper about full-length Tβ4 cannot automatically establish the same effects for TB-500. This guide identifies which material was studied rather than treating the names as interchangeable.

Potential benefits under investigation

Research on Tβ4 and related sequences has explored wound repair, cell migration, collagen deposition, blood-vessel formation and inflammatory responses. These are areas of scientific interest, not established benefits of using the QRP Research TB-500 product in people. The examples below describe the experimental material and model.

Tissue repair and collagen deposition

A study in diabetic and aged mice investigated full-length Tβ4 and a synthetic peptide containing its actin-binding domain. The researchers reported wound-repair activity; in diabetic mice, Tβ4 increased wound contraction and collagen deposition. This supports further investigation of repair mechanisms, but does not establish that a commercial TB-500 vial accelerates human injury recovery. Mouse wound-repair study

Cell movement and blood-vessel formation

In a rat skin-wound model, full-length Tβ4 was investigated for its effect on healing, including tissue repair and angiogenesis. These processes help explain scientific interest in the parent peptide. They do not demonstrate a clinical benefit from the shorter TB-500 fragment. Rat wound-healing study

Inflammatory responses and surface repair

In a mouse model of chemical injury to the cornea, topical full-length Tβ4 accelerated re-epithelialisation and reduced inflammatory-cell infiltration at measured time points. The findings concern a specific eye-injury model, not evidence that TB-500 reduces general inflammation or treats sports injuries in people. Corneal injury study

What do human studies show?

Human studies of full-length Tβ4 formulations should be read separately from evidence about the fragment. A placebo-controlled Phase II dry-eye study enrolled 72 participants. Neither primary efficacy endpoint showed a significant difference at the main assessment, although several secondary endpoints improved. The study used an ophthalmic Tβ4 formulation, not a TB-500 research vial. It does not establish safety or effectiveness for TB-500 injections or musculoskeletal recovery. Phase II dry-eye study

Safety and remaining uncertainties

The US FDA states that thymosin beta-4 fragment (LKKTETQ), also known as TB-500, may present immune-response risks related to aggregation and peptide impurities. It also reports that it has not identified human exposure data for drug products containing the fragment. This statement concerns the fragment and US compounding safety; it is not a conclusion about UK legal status. FDA safety information

WHAT YOU NEED — LABORATORY RESEARCH

Before laboratory work, have the labelled material and batch records; available identity, analysis and safety documentation; an approved experimental protocol; the protective equipment required by your laboratory's risk assessment; calibrated measuring equipment and compatible consumables; and arrangements for labelling, storage and waste disposal. The protocol and product-specific documentation must determine the solvent, preparation conditions and storage period.

Understanding the QRP Research 5 mg vial

The product page describes TB-500 as a lyophilised research peptide supplied at 5 mg per vial. That amount is the labelled material content, not a recommended human dose. Confirm the exact identity and batch documentation before designing an experiment. This guide provides no self-injection, dosing or reconstitution regimen. View TB-500 5 mg

How to review a certificate of analysis

Match the report to the product and batch. Check the stated sequence or molecular identity, laboratory, analysis date, methods and results. A chromatographic purity percentage is not the same as a verified mass of peptide per vial. It also does not establish sterility, absence of endotoxins or clinical safety. Ask for clarification if a report does not distinguish the fragment from full-length Tβ4. Browse the COA library

Frequently asked questions

Is TB-500 identical to full-length thymosin beta-4? No; the fragment discussed here is distinct from the 43-amino-acid parent peptide. Are wound-healing findings proof of human recovery benefits? No; the material, model and outcome need to match the proposed claim. Can a generic peptide guide determine how to prepare the vial for a laboratory experiment? No; use a validated method for the exact material. For missing batch documentation, contact QRP Research.

About this guide

Prepared for QRP Research. Sources checked on 28 September 2026. Educational overview for laboratory research, not medical advice. QRP Research supplies this material for non-clinical laboratory investigation, not human or veterinary administration. The cited studies did not test or certify QRP Research products.